Literature DB >> 22999130

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.

Uwe Siebert1, Oguzhan Alagoz, Ahmed M Bayoumi, Beate Jahn, Douglas K Owens, David J Cohen, Karen M Kuntz.   

Abstract

State-transition modeling is an intuitive, flexible, and transparent approach of computer-based decision-analytic modeling including both Markov model cohort simulation and individual-based (first-order Monte Carlo) microsimulation. Conceptualizing a decision problem in terms of a set of (health) states and transitions among these states, state-transition modeling is one of the most widespread modeling techniques in clinical decision analysis, health technology assessment, and health-economic evaluation. State-transition models have been used in many different populations and diseases, and their applications range from personalized health care strategies to public health programs. Most frequently, state-transition models are used in the evaluation of risk factor interventions, screening, diagnostic procedures, treatment strategies, and disease management programs. The goal of this article was to provide consensus-based guidelines for the application of state-transition models in the context of health care. We structured the best practice recommendations in the following sections: choice of model type (cohort vs. individual-level model), model structure, model parameters, analysis, reporting, and communication. In each of these sections, we give a brief description, address the issues that are of particular relevance to the application of state-transition models, give specific examples from the literature, and provide best practice recommendations for state-transition modeling. These recommendations are directed both to modelers and to users of modeling results such as clinicians, clinical guideline developers, manufacturers, or policymakers.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Mesh:

Year:  2012        PMID: 22999130     DOI: 10.1016/j.jval.2012.06.014

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  142 in total

1.  Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

Authors:  Verin Lertjanyakun; Nathorn Chaiyakunapruk; Susumu Kunisawa; Yuichi Imanaka
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

2.  Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study.

Authors:  Jose Leal; Alastair M Gray; Samuel Hawley; Daniel Prieto-Alhambra; Antonella Delmestri; Nigel K Arden; Cyrus Cooper; M Kassim Javaid; Andrew Judge
Journal:  J Bone Miner Res       Date:  2016-11-01       Impact factor: 6.741

3.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

4.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

5.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

6.  Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios.

Authors:  Paul E Parham; Dyfrig A Hughes
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-05       Impact factor: 6.237

7.  Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals.

Authors:  Tushar Srivastava; Nicholas R Latimer; Paul Tappenden
Journal:  Pharmacoeconomics       Date:  2021-05-19       Impact factor: 4.981

8.  Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies.

Authors:  Yaojen Chang; Lorenzo Gallon; Kirti Shetty; Yuchia Chang; Colleen Jay; Josh Levitsky; Bing Ho; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Transplantation       Date:  2015-02       Impact factor: 4.939

9.  Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.

Authors:  Yaojen Chang; Lorenzo Gallon; Colleen Jay; Kirti Shetty; Bing Ho; Josh Levitsky; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Liver Transpl       Date:  2014-09       Impact factor: 5.799

10.  Cost-utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort.

Authors:  Rebecca Forster; Aran Ratcliffe; Megan Lewis; Amy Crossley; Julio López Bastida; William C N Dunlop
Journal:  Eur J Health Econ       Date:  2018-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.